ZetaOmics is an oncology-focused Autonomous Computational Biologist released by Lantern Pharma Inc. on July 8, 2026. It aims to design cohorts and multi-omics analyses tailored to research questions—such as cancer types, patient cohorts, comparative conditions, and specific inquiries—presented in natural language, while linking computational tasks like differential expression, survival analysis, drug response assessment, and protein validation. While conventional conversational AI tools typically stop at suggesting analysis code, ZetaOmics functions closer to an analytical agent that translates research questions into statistically executable designs and guides result interpretation. In analogy, just as GPT reads natural language context to construct appropriate response structures, ZetaOmics interprets oncology research questions and translates them into cohort definitions and analytical procedures. In cancer multi-omics research, significant errors often occur at stages preceding code implementation. Ambiguous inclusion criteria for patient cohorts, imbalances in treatment history or cancer staging between comparison groups, or insufficient sample sizes leading to multiple gene testing can result in distorted conclusions even if the execution itself succeeds. The core differentiator of ZetaOmics lies in its integration of computational execution and statistical judgment rather than separating them. According to publicly available information, it is designed to detect errors and confounding factors within the input research design and prevent inappropriate analyses from being executed. Thus, it functions less as a tool that simply converts natural language into code and more as a digital co-researcher that first scrutinizes whether the research question aligns with data and statistical assumptions. Biotech researchers can utilize ZetaOmics as a starting point for exploratory analysis in fields where sample acquisition is challenging, such as rare cancers or pediatric oncology. For example, one could design a workflow to stratify patients of a specific cancer type by biomarker expression or clinical conditions, request differential expression analysis, and subsequently evaluate the survival association and drug response of candidate genes. However, it remains unclear from the provided information which databases are supported, how expression levels are normalized, what multiple testing correction methods are used, and how survival models and covariates are specified. Researchers must independently review cohort definitions, sample sizes, effect sizes, confidence intervals, and statistical assumptions before using the results for publications or clinical decision-making. Another potential application involves linking candidates discovered in transcriptomics to protein-level evidence or constructing patient subgroups where differential drug responses are anticipated. If a single natural language query can integrate differential expression, survival analysis, drug response, and protein validation, it can reduce manual data transfer between analytical tools and accelerate hypothesis generation. However, details regarding data upload support, patient data storage locations, encryption and deletion policies, and the feasibility of processing regulated clinical information must be verified through official terms of service. Based solely on currently public discovery information, there is no basis to regard ZetaOmics as a clinical diagnostic tool; research-grade analytical results require independent bioinformatics and biostatistical validation.

ZetaOmics is an oncology-focused Autonomous Computational Biologist released by Lantern Pharma Inc. on July 8, 2026. When researchers present cancer types, patient cohorts, comparative conditions, and research questions in natural language, ZetaOmics aims to design appropriate cohorts and multi-omics analyses, and to chain computational tasks such as differential expression, survival analysis, drug response prediction, and protein validation. While typical conversational AI tools merely suggest analysis code, ZetaOmics transforms research questions into statistically executable designs and guides users through result interpretation.

🔬 Differential Expression Candidate Exploration for Rare Cancers: Define rare cancer patients into biomarker-positive and -negative cohorts, then request differential expression analysis. Check sample size, stage, and treatment history imbalances as confounding factors. Validate candidate genes by reviewing multiple testing corrections and effect sizes, followed by validation in an independent cohort.